Home>Topics>Companies>Eli Lilly

Eli Lilly LLY

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. UPDATE 1-FDA recommends no changes to Lilly's schizophrenia injection use

      Headlines

      Mon, 23 Mar 2015

      March 23 (Reuters) - The U.S. Food and Drug Administration said it would not recommend changes to the prescribing or use of Eli Lilly and Co's schizophrenia drug after a review of two deaths.

    2. FDA recommends no changes to Lilly's schizophrenia injection use

      Headlines

      Mon, 23 Mar 2015

      March 23 (Reuters) - The U.S. Food and Drug Administration said it would not recommend changes to the prescribing or use of Eli Lilly and Co's schizophrenia drug after a review of two deaths.

    3. UPDATE 2-Pfizer, Lilly to resume study testing pain drug

      Headlines

      Mon, 23 Mar 2015

      March 23 (Reuters) - Pfizer Inc and Eli Lilly and Co will resume late-stage studies of their drug tanezumab for chronic pain after the U.S. Food and Drug Administration lifted a partial hold on trials of it and similar medicines.

    4. Pfizer, Lilly to resume late-stage study testing pain drug

      Headlines

      Mon, 23 Mar 2015

      March 23 (Reuters) - Pfizer Inc and Eli Lilly and Co said they planned to resume a late-stage study testing their pain drug tanezumab after the U.S. Food and Drug Administration lifted a partial...

    5. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

      Headlines

      Mon, 23 Mar 2015

      generic drug manufacturer to one of the largest specialty pharmaceutical companies, with sales on par with peers like Eli Lilly LLY and Bristol-Myers Squibb BMY. Only a few years ago, Watson was a U.S.-centric generic drug manufacturer with

    6. The Ultimate Stock-Pickers’ Top 10 Dividend Stocks

      Headlines

      Tue, 17 Mar 2015

      of our Ultimate Stock-Pickers since we last looked at them , with Vodafone Group VOD, Pfizer PFE, Roche RHHBY, and Eli Lilly LLY making way for Occidental Petroleum, National Oilwell Varco, Emerson Electric EMR , and Exxon Mobil. Yet the yields

    7. A Wide-Moat Opportunity in Health Care

      Video Reports

      Wed, 11 Mar 2015

      large branded-pharmaceutical firm with pro forma sales after the Allergan (AGN) deal on par with big players like Eli Lilly (LLY) and GlaxoSmithKline (GSK). We like the business and we give it a wide moat for three primary reasons. The

      Eli Lilly found at 0:21

      sales after the Allergan (AGN) deal on par with big players like Eli Lilly (LLY) and GlaxoSmithKline (GSK). We like the business and we give it a wide moat for three primary reasons. The first is
    8. UPDATE 1- Eli Lilly loses Alimta drug patent case in Germany to Actavis

      Headlines

      Fri, 6 Mar 2015

      March 6 (Reuters) - Eli Lilly has lost a patent case in Germany over its blockbuster Alimta lung cancer drug to generic producer Actavis, hitting the U.S. drugmaker's future sales hopes for the...

    9. Eli Lilly loses Alimta drug patent case in Germany to Actavis

      Headlines

      Fri, 6 Mar 2015

      March 6 (Reuters) - Eli Lilly said on Friday it had lost a patent case in Germany over its blockbuster Alimta lung cancer drug to generic drugmaker Actavis, hitting the U.S. drugmaker's future sales hopes for the medicine.

    10. FDA Ruling Redefines Testosterone Opportunity; Significantly Lowering Acrux Fair Value Estimate

      Commentary

      Wed, 4 Mar 2015

      recovering in the near term. Acrux's no-moat and very high fair value uncertainty ratings stand, given its reliance on Eli Lilly to invest in sales and marketing of lead product, Axiron.

    « Prev12345Next »
    Content Partners